Biotech

All Articles

After a challenging year, Exscientia folds up into Recursion

.After a year defined by pipe hairstyles, the shift of its chief executive officer and unemployments...

Cullinan, after $25M deal, return bispecific to Port

.Cullinan Therapy was actually made an impression on good enough along with Port BioMed's bispecific...

A more detailed consider Intense Biotech's Tough 15

.In this particular full week's incident of "The Top Line," we are actually diving into Intense Biot...

Lilly encounters period 2 failure of tau-targeting med

.The confetti is still soaring coming from Eli Lilly's gathering celebrating the approval of Alzheim...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our summary of significant leadership hirings, firings a...

Lykos will ask FDA to reevaluate its selection adhering to turndown of MDMA treatment for trauma

.Adhering to a bad presenting for Lykos Rehabs' MDMA candidate for trauma at a latest FDA advisory c...

AN 2 one-halfs head count, quits stage 3 test after data disappoint

.AN2 Rehabs is actually rethinking its own service in feedback to uninspired midphase data, pledging...

Merck pays for $700M for bispecific, snooping autoimmune opening and possibility to challenge Amgen in cancer

.Merck &amp Co. is paying $700 thousand in advance to challenge Amgen in a blood cancer cells market...

Gilead spends J&ampJ $320M to go out licensing deal for seladelpar

.Along With Gilead Sciences almost an FDA choice for its own liver ailment medicine seladelpar, the ...

' All palms on deck' at Lilly as peers target being overweight market

.CEO David Ricks can see the companies establishing tents at basecamp responsible for Eli Lilly in a...